Showing 5241-5250 of 9772 results for "".
- Potential Hair Growth Breakthrough: Researchers Grow Mature Hair Follicles in Labhttps://practicaldermatology.com/news/potential-hair-growth-breakthrough-researchers-grow-mature-hair-follicles-in-lab/2461398/Japanese researchers have successfully grown hair follicles in the lab. The team created a system that produces fully mature hair follicles as well as hair as long as 3 millimeters after a few weeks' growth. The in vitro hair follicle model adds to the understanding of ha
- Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosishttps://practicaldermatology.com/news/seborrheic-dermatitis-survey-shows-burdensome-and-lengthy-path-to-diagnosis/2461396/Arcutis Biotherapeutics, Inc., shared results of a nationwide survey of adults with seborrheic dermatitis and the health care providers who treat them that highlights the long path to diagnosis and the general lack of awareness and education about the disease. The online survey was conducted by T
- Aesthetics Biomedical's Vivace Ultra Wins FDA Clearancehttps://practicaldermatology.com/news/aesthetics-biomedicals-vivace-ultra/2461390/The FDA has given the nod to Aesthetics Biomedical Inc.’s Vivace Ultra for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. An innovative reimagination and technical upgrade of the legacy Vivace Microneedle RF device, the Vivace Ultra comb
- Thirdhand Smoke Linked to Contact Dermatitis, Psoriasishttps://practicaldermatology.com/news/thirdhand-linked-to-contact-dermatitis-psoriasis/2461389/Acute exposure to thirdhand smoke on the skin elevates biomarkers associated with the initiation of skin diseases, such as contact dermatitis and psoriasis. “We found exposure of human skin to THS initiates mechanisms of inflammatory skin disease, and elevate
- Study: Psoriasis Does Not Appear to Increase Heart Attack Risk in People with Significant Kidney Diseasehttps://practicaldermatology.com/news/study-psoriasis-does-not-appear-to-increase-heart-attack-risk-in-people-with-significant-kidney-disease/2461387/Studies have suggested that psoriasis is an independent risk factor for heart attack in the general population, but investigators recently found that in people who also have end-stage renal disease, which shares many risk factors with heart disease, it is not. “There are a lot of
- La Roche-Posay and the Women's Dermatologic Society Partner for Inaugural Diversity in Dermatology Fellowship at Howard Universityhttps://practicaldermatology.com/news/la-roche-posay-and-the-womens-dermatologic-society-partner-for-inaugural-diversity-in-dermatology-fellowship-at-howard-university/2461383/La Roche-Posay is partnering with the Women's Dermatologic Society (WDS) to sponsor a Fellowship in the Department of Dermatology at Howard University's College of Medicine for UIM medical students. The fellowship was created to support UIM candidates who are seeking additional clinical o
- Candesant Biomedical Introduces New SweatTech Initiative at ASDShttps://practicaldermatology.com/news/candesant-biomedical-novel-investigational-technology-for-hyperhydrosis/2461371/Candesant Biomedical is introducing a new initiative – SweatTech™ – at the ASDS annual meeting. The company is also developing a new novel technology (currently under FDA review) that reduces axillary hyperhidrosis. Their “TAT” (targeted alkali thermolysis) pat
- Almirall, Simcere Enter Into Licensing Agreement for IL-2-mu-Fchttps://practicaldermatology.com/news/almirall-simcere-enter-into-licensing-agreement-for-il-2-mu-fc/2461365/
- Johnson & Johnson Announces Kenvue as the Name for New Consumer Health Companyhttps://practicaldermatology.com/news/johnson-johnson-announces-kenvue-as-the-name-for-new-consumer-health-company/2461363/Johnson & Johnson’s planned new consumer health company will be named...Kenvue. Kenvue (pronounced ken·view), is inspired by two powerful ideas: “ken” – meaning knowledge, an English word primarily used in Scotland, and “vue,” ref
- Investigational Cannabinoid Receptor Agonist Proves Safe and Effective in Amyopathic Dermatomyositishttps://practicaldermatology.com/news/investigational-cannabinoid-receptor-agonist-proves-safe-and-effective-in-amyopathic-dermatomyositis/2461357/Lenabasum, a cannabinoid receptor agonist, is an effective and safe treatment for amyopathic dermatomyositis, a new study in the Journal of Investigative Dermatology suggests. This phase 2 trial, the